Navigation Links
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Date:12/9/2007

LFS compared with the current standard of care, which is no treatment after successful induction of remission. The improvement in LFS achieved by Ceplene + IL-2 was highly statistically significant at three years (p=0.0096, analyzed according to Intent-to-Treat).

In patients in their first remission, there was a 55 percent improvement in LFS. This represented an absolute improvement of more than 22 weeks in terms of delayed progression of the disease. This benefit was highly statistically significant, (p=0.011). This is the intended patient population for the Marketing Authorization Application submitted for Ceplene in Europe. The results of this trial were published in "Blood," a leading scientific journal in hematology, (Blood; The Journal of the American Society of Hematology, volume 108, number 1, July 1, 2006).

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company's broad portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is approaching a decision in Europe. In addition, EpiCept's ASAP technology, a proprietary live cell high-throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. EpiCept Corporation Announces Pricing of Public Offering
10. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
11. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... most persistent and deadliest infectious diseases in the world, ... Scientists who study tuberculosis have long debated its origins. ... in Africa to seals and sea lions that brought ... Native people there before Europeans landed on the continent. ... a Source of New World Human Tuberculosis," was published ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 As concerns ... of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological ... two U.S. Senators from New York are urging the ... recall of the devices. In a letter dated August ... also implored the agency to seriously consider the testimony ...
(Date:8/20/2014)... stimulates stress responses in adults, researchers at Yerkes ... that the amygdala has an inhibitory effect on ... primates. , The results are published this week ... amygdala is a region of the brain known ... and learning about threats. Alterations in the amygdala ...
(Date:8/20/2014)... HealthDay Reporter TUESDAY, Aug. 19, ... a baby,s immune system is twice as common as once ... says. This is the first evaluation of the effect ... as severe combined immunodeficiency (SCID), or "Bubble Boy" disease, the ... by the boy in the bubble, who was born without ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 The main ... 12 per diode panel band perfect spectrum that encompasses the ... most likely to use during photosynthesis. A key point ... is that they almost exclusively reside between 440-480 on the ... the red side of the spectrum. The KIND LED K3 ...
Breaking Medicine News(10 mins):Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2
... Vision ... Expand Access to Care, WASHINGTON, April 9, 2008 ... health care,policy issues by doctors of optometry from his district ... in West Virginia and the AOA are working to pass ...
... 9 Nu Skin Enterprises,Inc. (NYSE: NUS ) ... the market opening on Thursday, May 1, 2008., ... a,conference call with the investment community later that same ... can expect to hear,management review past results and discuss ...
... housework, is good for mental health , , WEDNESDAY, April 9 (HealthDay ... clean your house and boost your mood. , In ... activity a week helped mental health, although the more vigorous the ... published online Thursday in the British Journal of Sports Medicine ...
... 9 The following statement,was issued today by William ... York,s leaders have taken historic action to protect the ... use by increasing,the state cigarette tax by $1.25 to ... tax increase ever enacted and gives New York the,highest ...
... One month of tough breathing may help asthma sufferers breathe ... University of Houston professor. , In a move ... Hippocratic Oath first do no harm Richard Bond, ... long-standing medical taboo to treat asthma. Although counterintuitive, Bonds ...
... may also identify children at risk , , WEDNESDAY, April ... responsible for cardiac hypertrophy (thickening of the heart muscle) ... this rare but life-threatening condition in children, says a ... children who had no family history of the condition, ...
Cached Medicine News:Health News:Sen. Robert Byrd Receives AOA Health Care Leadership Award 2Health News:Whisk Those Blues Away 2Health News:New York Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 3Health News:First do no harm? UH prof taking opposite approach to treat asthma 4Health News:Gene Mutations for Rare Heart Disease Also Found in Kids 2
(Date:8/19/2014)... , Aug. 19, 2014   Lincor Inc. ... patient experience technology to New Jersey ... five-year agreement, CarePoint Health will deploy Lincor,s PatientLINC ... Center, Christ Hospital and Hoboken University Medical Center. ... range of software solutions to help hospitals reach ...
(Date:8/19/2014)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) (NW Bio), ... solid tumor cancers, announced today that the $17.5 million ... has closed.  The three-year notes have a 5% interest ... common stock.  The investors also have an option, exercisable ... 30% of these notes on the same terms. ...
(Date:8/19/2014)... 2014 Research and Markets has ... - Global Strategic Business Report" report to their ... markets for Pharmaceutical Contract Manufacturing in US$ Thousand by ... solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid ... Ointments). The report provides separate comprehensive analytics ...
Breaking Medicine Technology:Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2
Female Mini-VEST, Front Closure, X-Firm...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Female High Waist Briefs...
Short-Sleeve Bolero for targeted compression in the upper arms, back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Medicine Products: